ClinicalTrials.gg
CompletedNCT02054130Updated Dec 4, 2018Results posted

Study to Evaluate the Efficacy and Safety of MEDI9929 (AMG 157) in Adult Subjects With Inadequately Controlled, Severe Asthma

A Phase 2 interventional study of Placebo and MEDI9929 70 mg in Asthma, sponsored by MedImmune LLC. Completed at 107 sites in 12 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-12-04.

Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
584
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing tezepelumab in Asthma — 7 open to participants now, 8 under way, 5 of them phase 3. tezepelumab · Asthma.

Enrollment
4th of 28
584 · median 121
Started
2013
the only one that year
Phase 2
4 of 28
none open now
Registered
2nd of 28
by date
Lead sponsor
2 of 28
MedImmune LLC

Among the 28 studies testing tezepelumab in Asthma, this one is the 4th largest by enrollment, is the only one that started in 2013, is one of 4 in phase 2, and was the 2nd registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

7 of the 28 studies testing tezepelumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About tezepelumab

tezepelumab: first FDA approval 2021 (TEZSPIRE), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing tezepelumab in Asthma, or all of them as a file.
02

Study summary

The primary objective of the study is to evaluate the effect of 3 dose levels of MEDI9929 (AMG 157) on asthma exacerbations in adult subjects with inadequately controlled, severe asthma.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Asthma
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 through 75
  • (BMI) between 18-40 kg/m2 and weight greater than or equal 40 kg
  • Documented physician-diagnosed asthma - Subjects must have received a physician-prescribed asthma controller regimen with medium- or high-dose inhaled (ICS) plus long acting β2 agonist (LABA) -If on asthma controller medications in addition to ICS plus LABA, the dose of the other asthma controller medications (leukotriene receptor inhibitors, theophylline, secondary ICS, long-acting anti-muscarinics (LAMA), cromones, or maintenance oral prednisone or equivalent up to a maximum of 10 mg daily or 20 mg every other day for the maintenance treatment of asthma) must be stable. -Subjects must have a documented history of at least 2 asthma exacerbation events OR at least 1 severe asthma exacerbation resulting in hospitalization within the 12 months prior to first study visit.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of vocal cord dysfunction, reactive airways dysfunction syndrome, hyperventilation and panic attacks, or other mimics of asthma.
  • Current smokers or subjects with a smoking history of ≥ 10 pack years
  • Former smokers with \< 10 pack years must have stopped for at least 1 year to be eligible.
  • Any concomitant respiratory disease that in the opinion of the investigator and/or medical monitor will interfere with the evaluation of the product or interpretation of subject safety or study results (eg, , cystic fibrosis, pulmonary fibrosis, bronchiectasis, allergic bronchopulmonary aspergillosis, Churg-Strauss syndrome).
  • Evidence of active liver disease.
  • History of Cancer, except for basal cell carcinoma or insitu carcinoma of the cervix treated with apparent success with curative therapy or other are eligible provided that curative therapy was completed -Known history of active tuberculosis (TB)
  • History of anaphylaxis to any biologic therapy
  • Positive medical history for or C
  • Subject with (HIV) or subject taking antiretroviral medications, as determined by medical history and/or subject's verbal report.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
584 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received placebo matched to MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.

    Drug: Placebo

  • Experimental
    MEDI9929 70 mg

    Participants received 70 milligram (mg) of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.

    Drug: MEDI9929 70 mg

  • Experimental
    MEDI9929 210 mg

    Participants received 210 mg of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.

    Drug: MEDI9929 210 mg

  • Experimental
    MEDI9929 280 mg

    Participants received 280 mg of MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.

    Drug: MEDI9929 280 mg

Interventions

  • DrugPlacebo

    Participants received placebo matched to MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.

  • Participants received 70 milligram (mg) of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.

  • Participants received 210 mg of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.

  • Participants received 280 mg of MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.

06

What researchers measure

Primary outcomes

  1. Annualized Asthma Exacerbation Rate (AER) Through Week 52

    Asthma exacerbation is defined as worsening of asthma that leads to any of the following: use of systemic corticosteroids for at least 3 days, an emergency department visit due to asthma that required systemic corticosteroids, and an inpatient hospitalization due to asthma. The annual AER was presented as the total number of exacerbations for the treatment group divided by the total duration of person follow-up.

    Time frame: Week 0 (Day 1) up to Week 52

Secondary outcomes

  1. Reduction in AER on Subpopulations at Week 52

    Asthma exacerbation is defined as worsening of asthma that leads to any of the following: use of systemic corticosteroids for at least 3 days, an emergency department visit due to asthma that required systemic corticosteroids, and an inpatient hospitalization due to asthma. Reduction in AER was evaluated in pre-specified subpopulations (blood eosinophil count \[eosinophilic and non-eosinophilic\], T helper cell 2 \[Th2\] status \[high and low\], Fraction of exhaled nitric oxide \[FENO\] \[high and low\], serum periostin \[high and low\], current post bronchodilator forced expiratory volume in 1 second \[Post-BD FEV1\] reversibility- yes, allergic and non-allergic) of asthma. The annual AER was presented as the total number of exacerbations for the treatment group divided by the total duration of person follow-up. Also, the high or low was determined using median value.

    Time frame: Week 52

  2. Change From Baseline in Pre-bronchodilator (Pre-BD) Forced Expiratory Volume in 1 Second (FEV1) and Forced Vital Capacity (FVC) at Week 52

    Forced expiratory volume in 1 second and forced vital capacity measures taken before bronchodilator use were reported.

    Time frame: Baseline (Week 0 [Day 1]) to Week 52

  3. Change From Baseline in FEV1 on Subpopulations at Week 52

    Forced expiratory volume in one second (FEV1) was evaluated in pre-specified subpopulations of asthma. The data presented in the below table for this outcome measure is for pre-bronchodilator FEV1.

    Time frame: Baseline and up to Week 52

  4. Change From Baseline in Post-bronchodilator (Post-BD) FEV1 and FVC at Week 52

    Forced expiratory volume in 1 second and forced vital capacity measures taken after bronchodilator use were reported.

    Time frame: Baseline (Week 0 [Day 1]) to Week 52

  5. Change From Baseline in Overall Symptoms Score on Subpopulations at Week 52

    Asthma symptoms during night time and daytime are recorded by the participant in the asthma daily diary. Overall symptom score is the average of scores of daytime severity, daytime frequency, and nighttime severity symptoms. The daytime frequency and severity items are scored from 0 to 4, where a higher score indicates greater frequency/severity and nighttime severity item is scored from 0 to 4 , where a higher score indicates greater severity. Overall symptom score ranges from 0 to 4, where lower score indicates better asthma symptom while, higher score indicates worse asthma symptom.

    Time frame: Baseline and up to Week 52

  6. Change From Baseline in Asthma Symptoms Measured by Asthma Daily Diary at Week 52

    Asthma symptoms during night time and daytime are recorded by the participant in the asthma daily diary. Symptom score values for night time assessment is 0 (no asthma symptom) to 3 (unable to sleep because of asthma) and symptom score values for day time assessment is 0 (no asthma symptom) to 3 (unable to do normal activities due to asthma). Total asthma symptom score is the sum of the daytime and night time score (0 to 6). Lower score (0) is indicating better asthma symptom, while higher score (6) is indicating worse asthma symptom.

    Time frame: Baseline (Week 0 [Day 1]) and Week 52

  7. Change From Baseline in Asthma Symptoms Measured by Asthma Control Questionnaire (ACQ-6) Score at Week 52

    The ACQ is a patient-reported questionnaire assessing asthma symptoms (ie, night-time waking, symptoms on waking, activity limitation, shortness of breath, wheezing) and daily rescue bronchodilator use and FEV1. The ACQ-6 is a shortened version of the ACQ that omits the FEV1 measurement from the original ACQ score. Questions are weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled).

    Time frame: Baseline (Week 0 [Day 1]) and Week 52

  8. Rate of Severe Asthma Exacerbation Through Week 52

    A severe asthma exacerbation is defined as an event that resulted in hospitalization. The severe AER was presented as the total number of exacerbations for the treatment group divided by the total duration of person follow-up.

    Time frame: Week 0 (Day 1) up to Week 52

  9. Time to First Asthma Exacerbation Through Week 52

    Asthma exacerbation is defined as worsening of asthma that leads to use of systemic corticosteroids for at least 3 days, an emergency department visit due to asthma that required systemic corticosteroids, and an inpatient hospitalization due to asthma. Time to first asthma exacerbation was reported.

    Time frame: Week 0 (Day 1) through Week 52

  10. Time to First Severe Asthma Exacerbation Through Week 52

    Asthma exacerbation is defined as worsening of asthma that leads to use of systemic corticosteroids for at least 3 days, an emergency department visit due to asthma that required systemic corticosteroids, and an inpatient hospitalization due to asthma. Time to first severe asthma exacerbations (hospitalization) were reported.

    Time frame: Week 0 (Day 1) through Week 52

  11. Number of Participants With at Least One Asthma Exacerbations Through Week 52

    Asthma exacerbation is defined as worsening of asthma that leads to use of systemic corticosteroids for at least 3 days, an emergency department visit due to asthma that required systemic corticosteroids, and an inpatient hospitalization due to asthma.

    Time frame: Week 0 (Day 1) through Week 52

  12. Number of Participants With at Least One Severe Asthma Exacerbations Through Week 52

    Asthma exacerbation is defined as worsening of asthma that leads to use of systemic corticosteroids for at least 3 days, an emergency department visit due to asthma that required systemic corticosteroids, and an inpatient hospitalization due to asthma. Participants with severe asthma exacerbations (hospitalization) were reported.

    Time frame: Week 0 (Day 1) through Week 52

  13. Change From Baseline in Asthma Quality of Life Questionnaire (Standardized Version) (AQLQ [S]) Overall Score at Week 52

    The AQLQ(S) +12 is a 32-item questionnaire that measures the health-related quality of life experienced by asthma participants. The questionnaire comprises 4 separate domains (symptoms, activity limitations, emotional function, and environmental stimuli) scaled on a 7-point scale ranging from 7 (no impairment) to 1 (severe impairment).

    Time frame: Baseline (Week 0 [Day 1]) and Week 52

  14. Change From Baseline in European Quality of Life-5 Dimensions 5 Level Version (EQ-5D-5L) Health State Evaluation at Week 52

    European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) is a standardized measure of health status of the participant. The first component is a descriptive system of the respondent's health comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using the United Kingdom (UK) algorithm, with scores ranging from -0.594 to 1. A higher score indicates better health state. The second component is a self-perceived health score which is assessed using a visual analogue scale (VAS) that ranged from 0 to 100, where 0 indicated the worst health you can imagine and 100 indicated the best health you can imagine.

    Time frame: Baseline (Week 0 [Day 1]) and Week 52

  15. Total Amount of Study Drug Exposure

    The total amount of study drug exposure (in milligram) for the entire study period was summarized.

    Time frame: Week 0 (Day 1) through Week 52

  16. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

    An adverse event is any unfavourable and unintended signs (including abnormal laboratory findings), symptoms, or diseases temporally associated with use of medicinal product, whether or not considered related to medicinal product. Serious adverse event is any adverse event that resulted in death, life-threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, is a congenital anomaly/birth defect in offspring of a study participant, is an important medical event that may jeopardize the participant or may require medical intervention. TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug, for the period until and including the follow-up period (Week 64).

    Time frame: Day 1 upto Week 64

  17. Number of Participants With TEAEs Related to Vital Sign Parameters

    Adverse events observed in participants with clinically significant vital signs abnormalities were assessed.

    Time frame: Day 1 upto Week 64

  18. Number of Participants With TEAEs Related to Clinical Laboratory Evaluation

    An abnormal laboratory finding which required an action or intervention by the investigator, or a finding judged by the investigator to represent a change beyond the range of normal physiologic fluctuation were reported as an adverse event. Laboratory evaluations of blood and urine samples were performed.

    Time frame: Day 1 upto Week 64

  19. Number of Participants With TEAEs Related to Electrocardiogram Evaluations

    Adverse events observed in participants with clinically significant electrocardiogram abnormalities were assessed.

    Time frame: From the start of study drug administration upto Week 64

  20. Mean Serum Concentrations of MEDI9929

    The mean serum concentrations of MEDI9929 was observed at specified timepoints.

    Time frame: Week 0 (Day 1) to Week 64

  21. Number of Participants With Positive Antibodies to MEDI9929

    Blood samples for immunogenicity assessment included the determination of anti-drug antibodies (ADA) for MEDI9929. The number of participants with positive serum antibodies to MEDI9929 were presented.

    Time frame: Week 0 (Day 1) to Week 64

07

Results

Posted Dec 4, 2018
Limitations and caveats
A non-pre-specified statistical analysis was performed and generated the Measure of Dispersion for Outcome Measures 4 and 6.

Participant flow

The study was conducted from 19Dec2013 to 01Mar2017 across 12 countries (United States, Slovakia, Bulgaria, Czech Republic, Hungary, Israel, Japan, Latvia, Lithuania, Serbia, South Africa, and Ukraine). A total of 918 participants were recruited in the study.

Participant flow — Overall Study
MilestonePlaceboMEDI9929 70 mgMEDI9929 210 mgMEDI9929 280 mg
Started138138137137
Completed130127122115
Not completed8111522
Withdrew: Withdrawal by subject44710
Withdrew: Death0100
Withdrew: Lost to follow-up0012
Withdrew: Missed dose46710

Outcome measures

PrimaryAnnualized Asthma Exacerbation Rate (AER) Through Week 52

Asthma exacerbation is defined as worsening of asthma that leads to any of the following: use of systemic corticosteroids for at least 3 days, an emergency department visit due to asthma that required systemic corticosteroids, and an inpatient hospitalization due to asthma. The annual AER was presented as the total number of exacerbations for the treatment group divided by the total duration of person follow-up.

Time frame:
Week 0 (Day 1) up to Week 52
Reported as:
Number · events per person-year
Annualized Asthma Exacerbation Rate (AER) Through Week 52
events per person-yearPlaceboMEDI9929 70 mgMEDI9929 210 mgMEDI9929 280 mg
Annualized Asthma Exacerbation Rate (AER) Through Week 520.72 (0.59 to 0.88)0.27 (0.19 to 0.38)0.20 (0.13 to 0.30)0.23 (0.16 to 0.34)
Statistical analysis
  • Placebo vs MEDI9929 70 mg · Negative binomial regression · p = <0.001 · Rate ratio: 0.38 · 95% CI 0.23 to 0.63
  • Placebo vs MEDI9929 210 mg · Negative binomial regression · p = <0.001 · Rate ratio: 0.29 · 95% CI 0.16 to 0.51
  • Placebo vs MEDI9929 280 mg · Negative bnomial regression · p = <0.001 · Rate ratio: 0.34 · 95% CI 0.20 to 0.58
SecondaryReduction in AER on Subpopulations at Week 52

Asthma exacerbation is defined as worsening of asthma that leads to any of the following: use of systemic corticosteroids for at least 3 days, an emergency department visit due to asthma that required systemic corticosteroids, and an inpatient hospitalization due to asthma. Reduction in AER was evaluated in pre-specified subpopulations (blood eosinophil count \[eosinophilic and non-eosinophilic\], T helper cell 2 \[Th2\] status \[high and low\], Fraction of exhaled nitric oxide \[FENO\] \[high and low\], serum periostin \[high and low\], current post bronchodilator forced expiratory volume in 1 second \[Post-BD FEV1\] reversibility- yes, allergic and non-allergic) of asthma. The annual AER was presented as the total number of exacerbations for the treatment group divided by the total duration of person follow-up. Also, the high or low was determined using median value.

Time frame:
Week 52
Reported as:
Number · events per person-year
Reduction in AER on Subpopulations at Week 52
events per person-yearPlaceboMEDI9929 70 mgMEDI9929 210 mgMEDI9929 280 mg
Blood Eosinophil Count -Eosinophilic0.78 (0.59 to 1.00)0.29 (0.18 to 0.43)0.26 (0.16 to 0.42)0.21 (0.12 to 0.35)
Blood Eosinophil Count -Non-Eosinophilic0.65 (0.46 to 0.89)0.25 (0.14 to 0.42)0.14 (0.06 to 0.27)0.26 (0.14 to 0.43)
Th2 Status - High0.62 (0.45 to 0.83)0.33 (0.20 to 0.50)0.25 (0.14 to 0.41)0.21 (0.11 to 0.36)
Th2 Status - Low0.86 (0.64 to 1.13)0.23 (0.14 to 0.37)0.15 (0.07 to 0.28)0.26 (0.15 to 0.41)
FENO - High0.94 (0.72 to 1.20)0.32 (0.20 to 0.48)0.20 (0.11 to 0.35)0.20 (0.10 to 0.35)
FENO - Low0.51 (0.36 to 0.72)0.23 (0.13 to 0.38)0.21 (0.11 to 0.36)0.28 (0.16 to 0.44)
Serum Periostin - High0.78 (0.59 to 1.02)0.29 (0.17 to 0.45)0.19 (0.10 to 0.33)0.19 (0.10 to 0.32)
Serum Periostin - Low0.66 (0.48 to 0.89)0.27 (0.16 to 0.42)0.22 (0.12 to 0.38)0.30 (0.18 to 0.47)
Current Post-BD FEV1 Reversibility-Yes0.60 (0.47 to 0.75)0.26 (0.18 to 0.37)0.17 (0.10 to 0.27)0.21 (0.14 to 0.32)
Allergic0.75 (0.57 to 0.97)0.25 (0.15 to 0.40)0.14 (0.07 to 0.26)0.23 (0.13 to 0.38)
Non-Allergic0.65 (0.44 to 0.91)0.23 (0.12 to 0.39)0.26 (0.13 to 0.45)0.22 (0.11 to 0.38)
SecondaryChange From Baseline in Pre-bronchodilator (Pre-BD) Forced Expiratory Volume in 1 Second (FEV1) and Forced Vital Capacity (FVC) at Week 52

Forced expiratory volume in 1 second and forced vital capacity measures taken before bronchodilator use were reported.

Time frame:
Baseline (Week 0 [Day 1]) to Week 52
Reported as:
Mean · Liter
Change From Baseline in Pre-bronchodilator (Pre-BD) Forced Expiratory Volume in 1 Second (FEV1) and Forced Vital Capacity (FVC) at Week 52
LiterPlaceboMEDI9929 70 mgMEDI9929 210 mgMEDI9929 280 mg
Change from Baseline in Pre-BD FEV10.071 ± 0.4050.200 ± 0.4320.210 ± 0.4330.245 ± 0.411
Change from Baseline in Pre-BD FVC0.068 ± 0.4770.244 ± 0.5600.202 ± 0.6160.197 ± 0.484
SecondaryChange From Baseline in FEV1 on Subpopulations at Week 52

Forced expiratory volume in one second (FEV1) was evaluated in pre-specified subpopulations of asthma. The data presented in the below table for this outcome measure is for pre-bronchodilator FEV1.

Time frame:
Baseline and up to Week 52
Reported as:
Least squares mean · Liters
Change From Baseline in FEV1 on Subpopulations at Week 52
LitersPlaceboMEDI9929 70 mgMEDI9929 210 mgMEDI9929 280 mg
Blood Eosinophil Count -Eosinophilic-0.045 ± 0.0800.118 ± 0.0830.125 ± 0.0860.160 ± 0.080
Blood Eosinophil Count -Non-Eosinophilic-0.072 ± 0.105-0.030 ± 0.1120.008 ± 0.1060.011 ± 0.108
Th2 Status - High-0.058 ± 0.1010.037 ± 0.1090.052 ± 0.1070.182 ± 0.104
Th2 Status - Low-0.052 ± 0.0850.103 ± 0.0860.103 ± 0.0880.062 ± 0.086
FENO - High-0.054 ± 0.0780.093 ± 0.0840.137 ± 0.0830.155 ± 0.079
FENO - Low0.027 ± 0.0740.115 ± 0.0760.095 ± 0.0730.133 ± 0.075
Serum Periostin - High-0.017 ± 0.0880.147 ± 0.0940.207 ± 0.0920.185 ± 0.089
Serum Periostin - Low-0.040 ± 0.0900.060 ± 0.093-0.013 ± 0.0930.064 ± 0.089
Current Post-BD FEV1 Reversibility - Yes-0.081 ± 0.0750.052 ± 0.0770.049 ± 0.0770.066 ± 0.073
Allergic-0.047 ± 0.0730.131 ± 0.0810.084 ± 0.0770.065 ± 0.076
Non-Allergic-0.037 ± 0.1310.050 ± 0.1230.148 ± 0.1290.164 ± 0.123
SecondaryChange From Baseline in Post-bronchodilator (Post-BD) FEV1 and FVC at Week 52

Forced expiratory volume in 1 second and forced vital capacity measures taken after bronchodilator use were reported.

Time frame:
Baseline (Week 0 [Day 1]) to Week 52
Reported as:
Mean · Liter
Change From Baseline in Post-bronchodilator (Post-BD) FEV1 and FVC at Week 52
LiterPlaceboMEDI9929 70 mgMEDI9929 210 mgMEDI9929 280 mg
Change from Baseline in Post-BD FEV1-0.064 ± 0.3520.117 ± 0.3890.099 ± 0.4490.128 ± 0.415
Change from Baseline in Post-BD FVC-0.092 ± 0.3530.088 ± 0.4390.092 ± 0.5150.083 ± 0.435
SecondaryChange From Baseline in Overall Symptoms Score on Subpopulations at Week 52

Asthma symptoms during night time and daytime are recorded by the participant in the asthma daily diary. Overall symptom score is the average of scores of daytime severity, daytime frequency, and nighttime severity symptoms. The daytime frequency and severity items are scored from 0 to 4, where a higher score indicates greater frequency/severity and nighttime severity item is scored from 0 to 4 , where a higher score indicates greater severity. Overall symptom score ranges from 0 to 4, where lower score indicates better asthma symptom while, higher score indicates worse asthma symptom.

Time frame:
Baseline and up to Week 52
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Overall Symptoms Score on Subpopulations at Week 52
Units on a scalePlaceboMEDI9929 70 mgMEDI9929 210 mgMEDI9929 280 mg
Blood Eosinophil Count -Eosinophilic-0.57 ± 0.07-0.62 ± 0.07-0.78 ± 0.07-0.72 ± 0.07
Blood Eosinophil Count -Non-Eosinophilic-0.49 ± 0.08-0.60 ± 0.08-0.56 ± 0.08-0.72 ± 0.08
Th2 Status - High-0.54 ± 0.07-0.65 ± 0.08-0.62 ± 0.08-0.75 ± 0.08
Th2 Status - Low-0.50 ± 0.08-0.57 ± 0.07-0.72 ± 0.08-0.71 ± 0.08
FENO - High-0.52 ± 0.08-0.68 ± 0.07-0.75 ± 0.08-0.72 ± 0.08
FENO - Low-0.54 ± 0.07-0.55 ± 0.07-0.59 ± 0.08-0.71 ± 0.07
Serum Periostin - High-0.48 ± 0.07-0.54 ± 0.08-0.84 ± 0.08-0.74 ± 0.08
Serum Periostin - Low-0.58 ± 0.07-0.63 ± 0.07-0.47 ± 0.08-0.69 ± 0.07
Current Post-BD FEV1 Reversibility - Yes-0.55 ± 0.05-0.60 ± 0.06-0.64 ± 0.06-0.71 ± 0.06
Allergic-0.53 ± 0.07-0.59 ± 0.07-0.63 ± 0.07-0.67 ± 0.07
Non-Allergic-0.50 ± 0.09-0.60 ± 0.08-0.72 ± 0.09-0.85 ± 0.08
SecondaryChange From Baseline in Asthma Symptoms Measured by Asthma Daily Diary at Week 52

Asthma symptoms during night time and daytime are recorded by the participant in the asthma daily diary. Symptom score values for night time assessment is 0 (no asthma symptom) to 3 (unable to sleep because of asthma) and symptom score values for day time assessment is 0 (no asthma symptom) to 3 (unable to do normal activities due to asthma). Total asthma symptom score is the sum of the daytime and night time score (0 to 6). Lower score (0) is indicating better asthma symptom, while higher score (6) is indicating worse asthma symptom.

Time frame:
Baseline (Week 0 [Day 1]) and Week 52
Reported as:
Mean · Units on a scale
Change From Baseline in Asthma Symptoms Measured by Asthma Daily Diary at Week 52
Units on a scalePlaceboMEDI9929 70 mgMEDI9929 210 mgMEDI9929 280 mg
Daytime Severity-0.483 ± 0.700-0.657 ± 0.726-0.669 ± 0.640-0.680 ± 0.688
Daytime Frequency-0.493 ± 0.792-0.598 ± 0.837-0.727 ± 0.753-0.754 ± 0.752
Nighttime Severity-0.643 ± 0.799-0.616 ± 0.687-0.807 ± 0.699-0.662 ± 0.730
SecondaryChange From Baseline in Asthma Symptoms Measured by Asthma Control Questionnaire (ACQ-6) Score at Week 52

The ACQ is a patient-reported questionnaire assessing asthma symptoms (ie, night-time waking, symptoms on waking, activity limitation, shortness of breath, wheezing) and daily rescue bronchodilator use and FEV1. The ACQ-6 is a shortened version of the ACQ that omits the FEV1 measurement from the original ACQ score. Questions are weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled).

Time frame:
Baseline (Week 0 [Day 1]) and Week 52
Reported as:
Mean · Units on a scale
Change From Baseline in Asthma Symptoms Measured by Asthma Control Questionnaire (ACQ-6) Score at Week 52
Units on a scalePlaceboMEDI9929 70 mgMEDI9929 210 mgMEDI9929 280 mg
Change From Baseline in Asthma Symptoms Measured by Asthma Control Questionnaire (ACQ-6) Score at Week 52-0.89 ± 0.91-1.24 ± 0.94-1.17 ± 1.00-1.19 ± 1.00
SecondaryRate of Severe Asthma Exacerbation Through Week 52

A severe asthma exacerbation is defined as an event that resulted in hospitalization. The severe AER was presented as the total number of exacerbations for the treatment group divided by the total duration of person follow-up.

Time frame:
Week 0 (Day 1) up to Week 52
Reported as:
Number · events per person-year
Rate of Severe Asthma Exacerbation Through Week 52
events per person-yearPlaceboMEDI9929 70 mgMEDI9929 210 mgMEDI9929 280 mg
Rate of Severe Asthma Exacerbation Through Week 520.14 (0.08 to 0.22)0.04 (0.01 to 0.09)0.02 (0.00 to 0.07)0.03 (0.01 to 0.08)
SecondaryTime to First Asthma Exacerbation Through Week 52

Asthma exacerbation is defined as worsening of asthma that leads to use of systemic corticosteroids for at least 3 days, an emergency department visit due to asthma that required systemic corticosteroids, and an inpatient hospitalization due to asthma. Time to first asthma exacerbation was reported.

Time frame:
Week 0 (Day 1) through Week 52
Reported as:
Median · Days
Time to First Asthma Exacerbation Through Week 52
DaysPlaceboMEDI9929 70 mgMEDI9929 210 mgMEDI9929 280 mg
Time to First Asthma Exacerbation Through Week 52NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryTime to First Severe Asthma Exacerbation Through Week 52

Asthma exacerbation is defined as worsening of asthma that leads to use of systemic corticosteroids for at least 3 days, an emergency department visit due to asthma that required systemic corticosteroids, and an inpatient hospitalization due to asthma. Time to first severe asthma exacerbations (hospitalization) were reported.

Time frame:
Week 0 (Day 1) through Week 52
Reported as:
Median · Days
Time to First Severe Asthma Exacerbation Through Week 52
DaysPlaceboMEDI9929 70 mgMEDI9929 210 mgMEDI9929 280 mg
Time to First Severe Asthma Exacerbation Through Week 52NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryNumber of Participants With at Least One Asthma Exacerbations Through Week 52

Asthma exacerbation is defined as worsening of asthma that leads to use of systemic corticosteroids for at least 3 days, an emergency department visit due to asthma that required systemic corticosteroids, and an inpatient hospitalization due to asthma.

Time frame:
Week 0 (Day 1) through Week 52
Reported as:
Count of participants · Participants
Number of Participants With at Least One Asthma Exacerbations Through Week 52
ParticipantsPlaceboMEDI9929 70 mgMEDI9929 210 mgMEDI9929 280 mg
Number of Participants With at Least One Asthma Exacerbations Through Week 5243302125
SecondaryNumber of Participants With at Least One Severe Asthma Exacerbations Through Week 52

Asthma exacerbation is defined as worsening of asthma that leads to use of systemic corticosteroids for at least 3 days, an emergency department visit due to asthma that required systemic corticosteroids, and an inpatient hospitalization due to asthma. Participants with severe asthma exacerbations (hospitalization) were reported.

Time frame:
Week 0 (Day 1) through Week 52
Reported as:
Count of participants · Participants
Number of Participants With at Least One Severe Asthma Exacerbations Through Week 52
ParticipantsPlaceboMEDI9929 70 mgMEDI9929 210 mgMEDI9929 280 mg
Number of Participants With at Least One Severe Asthma Exacerbations Through Week 529534
SecondaryChange From Baseline in Asthma Quality of Life Questionnaire (Standardized Version) (AQLQ [S]) Overall Score at Week 52

The AQLQ(S) +12 is a 32-item questionnaire that measures the health-related quality of life experienced by asthma participants. The questionnaire comprises 4 separate domains (symptoms, activity limitations, emotional function, and environmental stimuli) scaled on a 7-point scale ranging from 7 (no impairment) to 1 (severe impairment).

Time frame:
Baseline (Week 0 [Day 1]) and Week 52
Reported as:
Mean · Units on a scale
Change From Baseline in Asthma Quality of Life Questionnaire (Standardized Version) (AQLQ [S]) Overall Score at Week 52
Units on a scalePlaceboMEDI9929 70 mgMEDI9929 210 mgMEDI9929 280 mg
Change From Baseline in Asthma Quality of Life Questionnaire (Standardized Version) (AQLQ [S]) Overall Score at Week 521.04 ± 1.111.19 ± 0.900.93 ± 1.031.13 ± 1.13
SecondaryChange From Baseline in European Quality of Life-5 Dimensions 5 Level Version (EQ-5D-5L) Health State Evaluation at Week 52

European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) is a standardized measure of health status of the participant. The first component is a descriptive system of the respondent's health comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using the United Kingdom (UK) algorithm, with scores ranging from -0.594 to 1. A higher score indicates better health state. The second component is a self-perceived health score which is assessed using a visual analogue scale (VAS) that ranged from 0 to 100, where 0 indicated the worst health you can imagine and 100 indicated the best health you can imagine.

Time frame:
Baseline (Week 0 [Day 1]) and Week 52
Reported as:
Mean · Units on a scale
Change From Baseline in European Quality of Life-5 Dimensions 5 Level Version (EQ-5D-5L) Health State Evaluation at Week 52
Units on a scalePlaceboMEDI9929 70 mgMEDI9929 210 mgMEDI9929 280 mg
Health State Valuation0.1051 ± 0.15110.0752 ± 0.21790.0729 ± 0.16240.0395 ± 0.1935
Visual Analog Scale13.8 ± 17.614.0 ± 16.412.0 ± 18.012.3 ± 18.0
SecondaryTotal Amount of Study Drug Exposure

The total amount of study drug exposure (in milligram) for the entire study period was summarized.

Time frame:
Week 0 (Day 1) through Week 52
Reported as:
Mean · Milligram
Total Amount of Study Drug Exposure
MilligramMEDI9929 70 mgMEDI9929 210 mgMEDI9929 280 mg
Total Amount of Study Drug Exposure877.0 ± 116.92493.9 ± 640.46574.9 ± 1630.2
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

An adverse event is any unfavourable and unintended signs (including abnormal laboratory findings), symptoms, or diseases temporally associated with use of medicinal product, whether or not considered related to medicinal product. Serious adverse event is any adverse event that resulted in death, life-threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, is a congenital anomaly/birth defect in offspring of a study participant, is an important medical event that may jeopardize the participant or may require medical intervention. TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug, for the period until and including the follow-up period (Week 64).

Time frame:
Day 1 upto Week 64
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
ParticipantsPlaceboMEDI9929 70 mgMEDI9929 210 mgMEDI9929 280 mg
TEAEs91939089
TESAEs18171318
SecondaryNumber of Participants With TEAEs Related to Vital Sign Parameters

Adverse events observed in participants with clinically significant vital signs abnormalities were assessed.

Time frame:
Day 1 upto Week 64
Reported as:
Count of participants · Participants
Number of Participants With TEAEs Related to Vital Sign Parameters
ParticipantsPlaceboMEDI9929 70 mgMEDI9929 210 mgMEDI9929 280 mg
Blood pressure diastolic increased0100
Blood pressure increased1210
Heart rate increased0001
Hypertension7756
Hypertensive crisis0001
Hypotension0002
Pyrexia0220
Respiratory rate increased0001
SecondaryNumber of Participants With TEAEs Related to Clinical Laboratory Evaluation

An abnormal laboratory finding which required an action or intervention by the investigator, or a finding judged by the investigator to represent a change beyond the range of normal physiologic fluctuation were reported as an adverse event. Laboratory evaluations of blood and urine samples were performed.

Time frame:
Day 1 upto Week 64
Reported as:
Count of participants · Participants
Number of Participants With TEAEs Related to Clinical Laboratory Evaluation
ParticipantsPlaceboMEDI9929 70 mgMEDI9929 210 mgMEDI9929 280 mg
Anaemia0001
Leukopenia0100
Lymphopenia0100
Neutropenia0100
Thrombocytopenia0100
Dyslipidaemia0100
Hepatic enzyme increased0010
Hypercholesterolaemia0010
Hyperuricaemia0010
Hypokalaemia0010
Vitamin D deficiency0010
Hematuria1010
SecondaryNumber of Participants With TEAEs Related to Electrocardiogram Evaluations

Adverse events observed in participants with clinically significant electrocardiogram abnormalities were assessed.

Time frame:
From the start of study drug administration upto Week 64
Reported as:
Count of participants · Participants
Number of Participants With TEAEs Related to Electrocardiogram Evaluations
ParticipantsPlaceboMEDI9929 70 mgMEDI9929 210 mgMEDI9929 280 mg
Atrial fibrillation1020
Atrial flutter0100
Bundle branch block left0010
Supraventricular extrasystoles1000
Tachycardia1112
SecondaryMean Serum Concentrations of MEDI9929

The mean serum concentrations of MEDI9929 was observed at specified timepoints.

Time frame:
Week 0 (Day 1) to Week 64
Reported as:
Mean · ng/mL
Mean Serum Concentrations of MEDI9929
ng/mLMEDI9929 70 mgMEDI9929 210 mgMEDI9929 280 mg
Week 43933.6 ± 3022.710733.1 ± 4649.439722.7 ± 15140.7
Week 126215.8 ± 3779.216625.4 ± 7751.663223.7 ± 60627.6
Week 206028.3 ± 2897.918237.1 ± 8721.964442.9 ± 22558.3
Week 286084.1 ± 2885.519373.4 ± 9191.464659.9 ± 24121.6
Week 406050.4 ± 3296.418926.1 ± 10252.764404.0 ± 26473.0
Week 526027.2 ± 3024.818821.9 ± 10435.268899.1 ± 71137.2
Week 64632.8 ± 519.51991.2 ± 1882.46986.0 ± 5289.0
SecondaryNumber of Participants With Positive Antibodies to MEDI9929

Blood samples for immunogenicity assessment included the determination of anti-drug antibodies (ADA) for MEDI9929. The number of participants with positive serum antibodies to MEDI9929 were presented.

Time frame:
Week 0 (Day 1) to Week 64
Reported as:
Count of participants · Participants
Number of Participants With Positive Antibodies to MEDI9929
ParticipantsPlaceboMEDI9929 70 mgMEDI9929 210 mgMEDI9929 280 mg
ADA Positive at Baseline7122
ADA prevalence13624
ADA incidence13513
Neutralizing antibody- ADA Positive0000

Adverse events

Collected over From Day 1 upto Week 64. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/138 (0%)18/138 (13%)56/138 (40.6%)
MEDI9929 70 mg1/138 (0.7%)17/138 (12.3%)49/138 (35.5%)
MEDI9929 210 mg0/137 (0%)13/137 (9.5%)44/137 (32.1%)
MEDI9929 280 mg0/137 (0%)18/137 (13.1%)50/137 (36.5%)
Most frequent serious events
Showing 10 of 59
Most frequent serious events
EventPlaceboMEDI9929 70 mgMEDI9929 210 mgMEDI9929 280 mg
AsthmaRespiratory, thoracic and mediastinal disorders10/1385/1384/1376/137
PneumoniaInfections and infestations1/1383/1380/1372/137
Cardiac failureCardiac disorders1/1380/1381/1370/137
Hiatus herniaGastrointestinal disorders0/1380/1380/1371/137
Large intestine polypGastrointestinal disorders0/1380/1380/1371/137
Pancreatitis acuteGastrointestinal disorders0/1380/1380/1371/137
Non-cardiac chest painGeneral disorders1/1380/1381/1370/137
CholelithiasisHepatobiliary disorders0/1380/1380/1371/137
Anaphylactic shockImmune system disorders0/1380/1380/1371/137
ErysipelasInfections and infestations0/1380/1380/1371/137
Most frequent other events
Most frequent other events
EventPlaceboMEDI9929 70 mgMEDI9929 210 mgMEDI9929 280 mg
AsthmaRespiratory, thoracic and mediastinal disorders47/13831/13823/13735/137
NasopharyngitisInfections and infestations16/13819/13819/13715/137
HeadacheNervous system disorders6/1386/13811/1375/137
BronchitisInfections and infestations7/1387/1385/1379/137

Baseline characteristics

The intent-to-treat population included participants who are randomized and received any study drug.

Age, Continuous
Age, Continuous(Years)PlaceboMEDI9929 70 mgMEDI9929 210 mgMEDI9929 280 mgTotal
Mean52.32 ± 11.7150.80 ± 12.3652.66 ± 12.6750.43 ± 12.2551.55 ± 12.25
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboMEDI9929 70 mgMEDI9929 210 mgMEDI9929 280 mgTotal
Female94898791361
Male44495046189
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboMEDI9929 70 mgMEDI9929 210 mgMEDI9929 280 mgTotal
Hispanic or Latino10124
Not Hispanic or Latino137138136135546
Unknown or Not Reported00000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboMEDI9929 70 mgMEDI9929 210 mgMEDI9929 280 mgTotal
Asian635519
Black or African American643619
White123131128122504
Other20024
Multiple Categories Checked10124
08

Study locations

107 sites
  • Research Site
    Los Angeles, California 90025, United States
  • Research Site
    Los Angeles, California 90048, United States
  • Research Site
    Miami, Florida 33133, United States
  • Research Site
    Oviedo, Florida 32765, United States
  • Research Site
    Savannah, Georgia 31406, United States
  • Research Site
    Peoria, Illinois 61602, United States
  • Research Site
    Baltimore, Maryland 21224, United States
  • Research Site
    Rochester, Minnesota 55905, United States
  • Research Site
    New York, New York 10016, United States
  • Research Site
    New York, New York 10029, United States
  • Research Site
    Charlotte, North Carolina 28207, United States
  • Research Site
    Charlotte, North Carolina 28277, United States
  • Research Site
    Dublin, Ohio 43016, United States
  • Research Site
    Oklahoma City, Oklahoma 73120, United States
  • Research Site
    Rock Hill, South Carolina 29732, United States
  • Research Site
    Spartanburg, South Carolina 29303, United States
  • Research Site
    Houston, Texas 77070, United States
  • Research Site
    Richmond, Virginia 23220, United States
  • Research Site
    Plovdiv, 4002, Bulgaria
  • Research Site
    Sofia, 1202, Bulgaria
  • Research Site
    Sofia, 1233, Bulgaria
  • Research Site
    Sofia, 1431, Bulgaria
  • Research Site
    Sofia, 1606, Bulgaria
  • Research Site
    Sofia, 1750, Bulgaria
  • Research Site
    Velingrad, 4600, Bulgaria
  • Research Site
    Brandys nad Labem, 250 01, Czechia
  • Research Site
    Hradec Kralove, 500 05, Czechia
  • Research Site
    Mlada Boleslav, 293 01, Czechia
  • Research Site
    Praha 4, 14059, Czechia
  • Research Site
    Praha 8, 180 00, Czechia
  • Research Site
    Praha 8, 180 81, Czechia
  • Research Site
    Strakonice, 38601, Czechia
  • Research Site
    Balassagyarmat, 2660, Hungary
  • Research Site
    Budapest, 1033, Hungary
  • Research Site
    Budapest, 1125, Hungary
  • Research Site
    Budapest, 1529, Hungary
  • Research Site
    Csorna, 9300, Hungary
  • Research Site
    Debrecen, 4032, Hungary
  • Research Site
    Farkasgyepü, 8582, Hungary
  • Research Site
    Gödöllő, 2100, Hungary
  • Research Site
    Komarom, 2900, Hungary
  • Research Site
    Mateszalka, 4700, Hungary
  • Research Site
    Nagykanizsa, 8800, Hungary
  • Research Site
    Szeged, H-6722, Hungary
  • Research Site
    Százhalombatta, 2440, Hungary
  • Research Site
    Torokbalint, 2045, Hungary
  • Research Site
    Ashkelon, 78278, Israel
  • Research Site
    Haifa, 34362, Israel
  • Research Site
    Jerusalem, 91120, Israel
  • Research Site
    Kfar-Saba, 44281, Israel
  • Research Site
    Petach Tikva, Israel
  • Research Site
    Rehovot, 7661041, Israel
  • Research Site
    Tel Hashomer, 52621, Israel
  • Research Site
    Chuo-ku, 103-0027, Japan
  • Research Site
    Chuo-ku, 103-0028, Japan
  • Research Site
    Chuo-ku, 104-8560, Japan
  • Research Site
    Fujisawa-shi, 251-8550, Japan
  • Research Site
    Kiyose-shi, 204-8585, Japan
  • Research Site
    Kurume-shi, 830-0011, Japan
  • Research Site
    Maebashi-shi, 371-0054, Japan
  • Research Site
    Ora-gun, 370-0615, Japan
  • Research Site
    Sagamihara-shi, 228-0815, Japan
  • Research Site
    Saitama-Ken, 338-8553, Japan
  • Research Site
    Sapporo-shi, 060-0033, Japan
  • Research Site
    Taito-ku, 111-0051, Japan
  • Research Site
    Toshima-ku, 171-0014, Japan
  • Research Site
    Yokkaichi-shi, 510-8567, Japan
  • Research Site
    Daugavpils, LV-5401, Latvia
  • Research Site
    Rezekne, LV-4600, Latvia
  • Research Site
    Riga, 1001, Latvia
  • Research Site
    Riga, LV-1038, Latvia
  • Research Site
    Riga, LV1002, Latvia
  • Research Site
    Riga, LV1010, Latvia
  • Research Site
    Kaunas, LT50009, Lithuania
  • Research Site
    Klaipeda, 92231, Lithuania
  • Research Site
    Klaipeda, 92288, Lithuania
  • Research Site
    Belgrade, 11000, Serbia
  • Research Site
    Kragujevac, 34000, Serbia
  • Research Site
    Sremska Kamenica, 21204, Serbia
  • Research Site
    Bardejov, 085 01, Slovakia
  • Research Site
    Bratislava, 84108, Slovakia
  • Research Site
    Ilava, 01901, Slovakia
  • Research Site
    Kosice, 040 01, Slovakia
  • Research Site
    Levice, 934 01, Slovakia
  • Research Site
    Nove Zamky, 940 01, Slovakia
  • Research Site
    Poprad, 058 01, Slovakia
  • Research Site
    Spisska Nova Ves, 052 01, Slovakia
  • Research Site
    Sturovo, 94301, Slovakia
  • Research Site
    Surany, 94201, Slovakia
  • Research Site
    Topolcany, 95501, Slovakia
  • Research Site
    Zvolen, 96001, Slovakia
  • Research Site
    Durban, 4068, South Africa
  • Research Site
    Middelburg, 1055, South Africa
  • Research Site
    Pretoria, 0181, South Africa
  • Research Site
    Pretoria, 0183, South Africa
  • Research Site
    Dnipropetrovsk, 49051, Ukraine
  • Research Site
    Ivano-Frankivsk, 76012, Ukraine
  • Research Site
    Kyiv, 02091, Ukraine
  • Research Site
    Kyiv, 03680, Ukraine
  • Research Site
    Kyiv, 04050, Ukraine

Showing the first 100 of 107 sites across 12 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Corren J, Parnes JR, Wang L, Mo M, Roseti SL, Griffiths JM, van der Merwe R. Tezepelumab in Adults with Uncontrolled Asthma. N Engl J Med. 2017 Sep 7;377(10):936-946. doi: 10.1056/NEJMoa1704064. Erratum In: N Engl J Med. 2019 May 23;380(21):2082. doi: 10.1056/NEJMx180026. PubMed 28877011 ↗
  • Corren J, Pham TH, Garcia Gil E, Salapa K, Ren P, Parnes JR, Colice G, Griffiths JM. Baseline type 2 biomarker levels and response to tezepelumab in severe asthma. Allergy. 2022 Jun;77(6):1786-1796. doi: 10.1111/all.15197. Epub 2022 Feb 9. PubMed 34913186 ↗
  • Corren J, Ambrose CS, Salapa K, Roseti SL, Griffiths JM, Parnes JR, Colice G. Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma and Perennial Allergy. J Allergy Clin Immunol Pract. 2021 Dec;9(12):4334-4342.e6. doi: 10.1016/j.jaip.2021.07.045. Epub 2021 Aug 3. PubMed 34358701 ↗
  • Ly N, Zheng Y, Griffiths JM, van der Merwe R, Agoram B, Parnes JR, Roskos L. Pharmacokinetic and Pharmacodynamic Modeling of Tezepelumab to Guide Phase 3 Dose Selection for Patients With Severe Asthma. J Clin Pharmacol. 2021 Jul;61(7):901-912. doi: 10.1002/jcph.1803. Epub 2021 Jan 16. PubMed 33368307 ↗
  • Corren J, Garcia Gil E, Griffiths JM, Parnes JR, van der Merwe R, Salapa K, O'Quinn S. Tezepelumab improves patient-reported outcomes in patients with severe, uncontrolled asthma in PATHWAY. Ann Allergy Asthma Immunol. 2021 Feb;126(2):187-193. doi: 10.1016/j.anai.2020.10.008. Epub 2020 Oct 23. PubMed 33169672 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2013 to primary completion in Dec 2016, 35 months.

Results were first posted in Dec 2018, 1 year 11 months after primary completion.

Of 137 industry-sponsored phase 2 interventional studies under Asthma, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 35 months is above that.

Counting every sponsor, half of 199 studies reached it within 20 months; a quarter within 12 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2013
First posted
Feb 4, 2014
StartActual
Dec 13, 2013
Primary completionActual
Dec 12, 2016
CompletionActual
Mar 1, 2017
Results first posted
Dec 4, 2018
Last update
Dec 4, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02054130
Lead sponsor
MedImmune LLC
Collaborators
Amgen
Responsible party
Sponsor
First posted
Feb 4, 2014
Start date
Dec 13, 2013
Primary completion
Dec 12, 2016
Completion
Mar 1, 2017
Results posted
Dec 4, 2018
Last update
Dec 4, 2018

Study contacts

MedImmune LLC
study director · MedImmune LLC

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tezepelumab

Start the discussion